# KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

> **NCT02867007** · PHASE1 · COMPLETED · sponsor: **Kyowa Kirin, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Solid Tumor
- Cancer
- Carcinoma

## Interventions

- **DRUG:** KHK2455
- **DRUG:** Mogamulizumab

## Key facts

- **NCT ID:** NCT02867007
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2019-12-15
- **Final completion:** 2019-12-15
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02867007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02867007, "KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02867007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*